In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for ...

A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

A team of Ohio State researchers engineered a new antibody that could revolutionize influenza prevention through a nasal ...

Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully ...

The engineered molecule is based on the IgM version of an immunoglobulin antibody, the generic first line of antibody defense against infection -- but with an added structural feature that ...

The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin eye drop for the treatment of dry eye disease, according to a press release ...

The following is a summary of “Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.